Genialis

Boston, MA · Privately Held (backing)

Developer of an AI-driven cancer biology platform designed to predict how therapies will perform in patients. Genialis is based in Boston, MA. Its last reported valuation was $37 million in Jan 2023. It has raised $16.4 million across 2 recorded rounds; the latest was a $700,000 seed round in Dec 2025.

Last reported valuation
$37.0M
Oct 2026
Priced at
—
Total raised
$16.4M
Last round
Seed Round
Dec 2025

Who backs Genialis?

9 investors
InvestorType
RedalpineVenture capital
Rajeev SuratiAngel
Debiopharm Innovation Fund—
Drew Volpe—
First Star Ventures—
Horizon 2020—
P5 Health Ventures—
Pikas—
Taiwania Capital—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Genialis investors

9 investors are on record for Genialis, including Redalpine, Rajeev Surati, Debiopharm Innovation Fund and Drew Volpe. The seed round in Dec 2025 drew 2 investors.

Free account
More of Genialis with a free account
  • ·Watch Genialis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like Genialis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View